RecruitingPhase 4NCT07074418

Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2

Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2 - EMPA [10-20]

Sponsor

Centre Hospitalier Universitaire de Nice

Enrollment

34 participants

Start Date

Aug 25, 2026

Study Type

INTERVENTIONAL

Conditions

Chronic Kidney Diseases

Summary

The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Empagliflozin 10 MG then Placebo and a drug called Placebo then Empagliflozin 10 MG for people with chronic kidney diseases. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.